CoChat

The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.

Design and validation of novel brain-penetrant HCN channel inhibitors to ameliorate social stress-induced susceptible phenotype

Open access

Abstract

Major Depressive Disorder (MDD) is a devastating, multifactorial disease with limited pharmacological treatment options. Patients with MDD exhibit alterations in their dopamine (DA) signaling pathways through the midbrain ventral tegmental area (VTA). A similar observation is also detected in preclinical models of stress - mice exhibit behavioral and physiological impairments following chronic social defeat stress (CSDS). Prior studies demonstrate that CSDS-susceptible mice have increased VTA DA neuronal excitability, in part driven by an upregulation in hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels. Inhibiting HCN channels with known inhibitors such as Cilobradine alleviates the negative behavioral effects of CSDS. Here, we aimed to identify Cilobradine analogs with improved neural tropism and inhibitory efficacy. Two compounds, MS7710 and MS7712 , differing by their left-hand side moieties, have a similar, potent inhibitory effect on VTA DA I h currents as compared to Cilobradine, and a greater inhibitory effect than Cilobradine on VTA DA firing rate. We demonstrate that MS7710 and MS7712 have superior brain/plasma concentration ratios as compared to Cilobradine. They were efficacious at inhibiting VTA DA neuron firing rate and bursting activity in CSDS-susceptible male mice at lower doses than Cilobradine, which was recapitulated in female CSDS-susceptible mice with MS7710 . Finally, we define that a single intraperitoneal injection of MS7710 ameliorates CSDS-induced social interaction deficits and reward-associated cognitive inflexibility for at least two weeks in male and female mice. These findings yield a novel HCN channel inhibitor with improved neural tropism and stress-alleviating effects that could provide a basis for future antidepressant drug discovery.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-025-02972-8

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Chemical structures of Cilobradine, Ivabradine and Zatebradine and their analogs designed and synthesized to improve BBB permeability. a Structures of Cilobradine, Ivabradine and Zatebradine. b Novel analogs that are designed, synthesized and used in this study. Modifications to the substituents of the left-hand side phenyl ring are highlighted in blue. The alteration of the central piperidine ring of Cilobradine to a morpholine ring is represented by the introduced oxygen highlighted in orange. The replacement of the benzylic methylene group of Zatebradine with a difluoromethylene group is highlighted in pink.
Fig. 1 Chemical structures of Cilobradine, Ivabradine and Zatebradine and their analogs designed and synthesized to improve BBB permeability. a Structures of Cilobradine, Ivabradine and Zatebradine. b Novel analogs that are designed, synthesized and used in this study. Modifications to the substituents of the left-hand side phenyl ring are highlighted in blue. The alteration of the central piperidine ring of Cilobradine to a morpholine ring is represented by the introduced oxygen highlighted in orange. The replacement of the benzylic methylene group of Zatebradine with a difluoromethylene group is highlighted in pink.CC BY-NC-ND · PubMed Central
Fig. 2 Novel HCN inhibitors exhibit a range of efficacy on VTA dopamine neurons compared to parent compounds. a Experimental schematic of brain slice electrophysiology with local application. b Example image of VTA DA neuron (denoted with > and a circle), the patch pipette (denoted with >>), and the local application pipette (denoted with >>>). c Sample trace of Ih inhibition evoked at -120 mV of VTA DA neurons before (gray) and after (black) compound application. Sample traces and percent inhibition of Ih currents in VTA DA neurons following local compound application of: d Ivabradine, Zatebradine, and 8 (n = 4-9, H4/26 = 16.82, p = 0.0004; Zatebradine vs. vehicle, ** p = 0.0064; Ivabradine vs. vehicle, * p = 0.0144), and e Cilobradine and Cilobradine novel analogs (n = 4-11, H9/60 = 42.94, p < 0.0001; 1 vs. vehicle, ** p = 0.0049; MS7712 vs. vehicle, ** p = 0.0012; MS7710 vs. vehicle, *** p = 0.0002; Cilobradine vs. vehicle, *** p < 0.0001). Sample traces and percent inhibition of firing rate in VTA DA neurons following local compound application of: f Ivabradine and Zatebradine (n = 6–10, H3/25 = 16.66, p = 0.0002; Zatebradine vs. vehicle, ** p = 0.0040; Ivabradine vs. vehicle, *** p = 0.0003), and g Cilobradine and top analogs (n = 7-13, H3/29 = 10.03, p = 0.0067; MS7712 vs. Cilobradine, ** p = 0.0066; MS7710 vs. Cilobradine, * p = 0.0244). All scale bars are 200 pA vs. 1 s for Ih currents and 1 mV vs. 2 s, all baseline sample traces are in gray, and all colored traces are post-compound application. All data are presented as mean ± SEM, analyzed with Kruskal-Wallis tests and corrected for multiple comparisons with Dunn’s tests.* p < 0.05, ** p < 0.01, *** p < 0.001.
Fig. 2 Novel HCN inhibitors exhibit a range of efficacy on VTA dopamine neurons compared to parent compounds. a Experimental schematic of brain slice electrophysiology with local application. b Example image of VTA DA neuron (denoted with > and a circle), the patch pipette (denoted with >>), and the local application pipette (denoted with >>>). c Sample trace of Ih inhibition evoked at -120 mV of VTA DA neurons before (gray) and after (black) compound application. Sample traces and percent inhibition of Ih currents in VTA DA neurons following local compound application of: d Ivabradine, Zatebradine, and 8 (n = 4-9, H4/26 = 16.82, p = 0.0004; Zatebradine vs. vehicle, ** p = 0.0064; Ivabradine vs. vehicle, * p = 0.0144), and e Cilobradine and Cilobradine novel analogs (n = 4-11, H9/60 = 42.94, p < 0.0001; 1 vs. vehicle, ** p = 0.0049; MS7712 vs. vehicle, ** p = 0.0012; MS7710 vs. vehicle, *** p = 0.0002; Cilobradine vs. vehicle, *** p < 0.0001). Sample traces and percent inhibition of firing rate in VTA DA neurons following local compound application of: f Ivabradine and Zatebradine (n = 6–10, H3/25 = 16.66, p = 0.0002; Zatebradine vs. vehicle, ** p = 0.0040; Ivabradine vs. vehicle, *** p = 0.0003), and g Cilobradine and top analogs (n = 7-13, H3/29 = 10.03, p = 0.0067; MS7712 vs. Cilobradine, ** p = 0.0066; MS7710 vs. Cilobradine, * p = 0.0244). All scale bars are 200 pA vs. 1 s for Ih currents and 1 mV vs. 2 s, all baseline sample traces are in gray, and all colored traces are post-compound application. All data are presented as mean ± SEM, analyzed with Kruskal-Wallis tests and corrected for multiple comparisons with Dunn’s tests.* p < 0.05, ** p < 0.01, *** p < 0.001.CC BY-NC-ND · PubMed Central
Fig. 3 Novel HCN inhibitors MS7710 and MS7712 exhibit improved BBB permeability compared to their parent compound Cilobradine. a Experimental timeline for BBB permeability testing in stress-naïve, male and female, C57BL/6 mice – brain and blood samples were taken at time points 15 min, 1 h, and 4 h post-IP injection of 20 mg/kg of each compound. b Schematic of sample collection. c Cilobradine brain and plasma concentrations for male mice (n = 3/timepoint/condition, ANOVA F(condition)1,12 = 148.6, *** p < 0.0001, F(time)2,12 = 15.73, *** p = 0.0004, F(time x condition)2,12 = 12.80, ** p = 0.0011) and ratio of 0.076. d MS7710 brain and plasma concentrations for male mice (n = 3/timepoint/condition, ANOVA F(condition)1,12 = 21.28, *** p = 0.0006, F(time)2,12 = 58.25, *** p < 0.0001, F(time x condition)2,12 = 5.663, * p = 0.0185) and ratio of 0.42. e MS7712 brain and plasma concentrations for male mice (n = 3/timepoint/condition, ANOVA F(condition)1,12 = 1.062, p ns, F(time)2,12 = 692.7, *** p < 0.0001, F(time x condition)2,12 = 12.97, ** p = 0.0010) and ratio of 0.86. f Cilobradine brain and plasma concentrations for female mice (n = 3/timepoint/condition, ANOVA F(condition)1,12 = 426.9, *** p < 0.0001, F(time)2,12 = 91.61, *** p < 0.0001, F(time x condition)2,12 = 85.77, *** p < 0.0001) and ratio of 0.029. g MS7710 brain and plasma concentrations and ratio of 0.21 for female mice (n = 3/timepoint/condition, ANOVA F(condition)1,12 = 783.1, *** p < 0.0001 F(time)2,12 = 1014, *** p < 0.0001, F(time x condition)2,12 = 377.8, *** p < 0.0001). h MS7712 brain and plasma concentrations and ratio of 0.34 for female mice (n = 3/timepoint/condition, ANOVA F(condition)1,12 = 195.6, *** p < 0.0001, F(time)2,12 = 469.3, *** p < 0.0001, F(time x condition)2,12 = 59.09, *** p < 0.0001). Data represented by mean ± SEM.
Fig. 3 Novel HCN inhibitors MS7710 and MS7712 exhibit improved BBB permeability compared to their parent compound Cilobradine. a Experimental timeline for BBB permeability testing in stress-naïve, male and female, C57BL/6 mice – brain and blood samples were taken at time points 15 min, 1 h, and 4 h post-IP injection of 20 mg/kg of each compound. b Schematic of sample collection. c Cilobradine brain and plasma concentrations for male mice (n = 3/timepoint/condition, ANOVA F(condition)1,12 = 148.6, *** p < 0.0001, F(time)2,12 = 15.73, *** p = 0.0004, F(time x condition)2,12 = 12.80, ** p = 0.0011) and ratio of 0.076. d MS7710 brain and plasma concentrations for male mice (n = 3/timepoint/condition, ANOVA F(condition)1,12 = 21.28, *** p = 0.0006, F(time)2,12 = 58.25, *** p < 0.0001, F(time x condition)2,12 = 5.663, * p = 0.0185) and ratio of 0.42. e MS7712 brain and plasma concentrations for male mice (n = 3/timepoint/condition, ANOVA F(condition)1,12 = 1.062, p ns, F(time)2,12 = 692.7, *** p < 0.0001, F(time x condition)2,12 = 12.97, ** p = 0.0010) and ratio of 0.86. f Cilobradine brain and plasma concentrations for female mice (n = 3/timepoint/condition, ANOVA F(condition)1,12 = 426.9, *** p < 0.0001, F(time)2,12 = 91.61, *** p < 0.0001, F(time x condition)2,12 = 85.77, *** p < 0.0001) and ratio of 0.029. g MS7710 brain and plasma concentrations and ratio of 0.21 for female mice (n = 3/timepoint/condition, ANOVA F(condition)1,12 = 783.1, *** p < 0.0001 F(time)2,12 = 1014, *** p < 0.0001, F(time x condition)2,12 = 377.8, *** p < 0.0001). h MS7712 brain and plasma concentrations and ratio of 0.34 for female mice (n = 3/timepoint/condition, ANOVA F(condition)1,12 = 195.6, *** p < 0.0001, F(time)2,12 = 469.3, *** p < 0.0001, F(time x condition)2,12 = 59.09, *** p < 0.0001). Data represented by mean ± SEM.CC BY-NC-ND · PubMed Central
Fig. 4 Novel HCN inhibitors MS7710 and MS7712 reverse CSDS-induced hyperdopaminergia in male CSDS-susceptible mice. a Experimental timeline for CSDS and in vivo electrophysiology. b SI ratios of the male CSDS mice before in vivo electrophysiological recordings (n = 6,8,9; p = 0.36). c Example in vivo electrophysiology trace of firing rate in VTA DA neurons in CSDS-susceptible mice. d Examples of tonic activity (yellow box labeled i) and phasic (bursting) activity (red box labeled ii). e Classical waveform of a VTA DA neuron, averaged over 50 spikes (scale bar 20 mV vs. 1 ms). f Sample traces of baseline firing rate and firing rate following a 20 mg/kg IP injection of Cilobradine (scale bars 0.05 mV vs. 1 s). Summary and inset cumulative distribution (dotted horizontal line represents 100%) of: g firing rate in VTA DA neurons during baseline conditions (0 mg/kg Cilobradine; n = 57/17) or post-IP injection of 20 mg/kg Cilobradine (n = 44/11; * p = 0.0184), and h bursting activity in VTA DA neurons during baseline conditions (0 mg/kg Cilobradine; n = 57/17) or post-IP injection of 20 mg/kg Cilobradine (n = 44/11; *** p = 0.0001). i Sample traces of baseline firing rate and firing rate following an IP injection of 1 mg/kg and 10 mg/kg MS7712. Summary and inset cumulative distribution of: j firing rate in VTA DA neurons during baseline conditions (0 mg/kg MS7712; n = 17/6) or post-IP injection of 1 mg/kg (n = 21/3) or 10 mg/kg (n = 22/3) MS7712 (H3/60 = 23.42, p < 0.0001; 10 mg/kg MS7712 vs. baseline, *** p < 0.0001), and k bursting activity in VTA DA neurons during baseline conditions (0 mg/kg MS7712; n = 17/6) or post-IP injection of 1 mg/kg (n = 21/3) or 10 mg/kg (n = 22/3) MS7712 (H3/60 = 11.38, p = 0.0034; 10 mg/kg MS7712 vs. baseline, **p = 0.0023). l Sample traces of firing rate following an IP injection of 1 and 10 mg/kg MS7710. Summary and inset cumulative distribution of m firing rate in VTA DA neurons during baseline conditions (0 mg/kg MS7710; n = 27/8) or post-IP injection of 1 mg/kg (n = 15/3) or 10 mg/kg (n = 18/3) MS7710 (H3/59 = 14.97, p = 0.0006; 1 mg/kg MS7710 vs. baseline, * p = 0.0150; 10 mg/kg MS7710 vs. baseline, *** p = 0.0007) and n bursting activity in VTA DA neurons during baseline conditions (0 mg/kg MS7710; n = 27/8) or post-IP injection of 1 mg/kg (n = 15/3) or 10 mg/kg (n = 18/3) MS7710 (H3/59 = 7.752, * p = 0.0207; 1 mg/kg MS7710 vs. baseline, * p = 0.0494; 10 mg/kg MS7710 vs. baseline, * p = 0.0364). All sample trace scale bars 0.1 mV vs. 1 s unless otherwise noted. Notation of n = ntotal cells/ntotal mice. Data are presented as median ± quartiles ± min and max, analyzed by the Mann-Whitney test for two groups or the Kruskal-Wallis test for three groups, followed by Dunn’s test for multiple comparisons. * p < 0.05, ** p < 0.01, *** p < 0.001.
Fig. 4 Novel HCN inhibitors MS7710 and MS7712 reverse CSDS-induced hyperdopaminergia in male CSDS-susceptible mice. a Experimental timeline for CSDS and in vivo electrophysiology. b SI ratios of the male CSDS mice before in vivo electrophysiological recordings (n = 6,8,9; p = 0.36). c Example in vivo electrophysiology trace of firing rate in VTA DA neurons in CSDS-susceptible mice. d Examples of tonic activity (yellow box labeled i) and phasic (bursting) activity (red box labeled ii). e Classical waveform of a VTA DA neuron, averaged over 50 spikes (scale bar 20 mV vs. 1 ms). f Sample traces of baseline firing rate and firing rate following a 20 mg/kg IP injection of Cilobradine (scale bars 0.05 mV vs. 1 s). Summary and inset cumulative distribution (dotted horizontal line represents 100%) of: g firing rate in VTA DA neurons during baseline conditions (0 mg/kg Cilobradine; n = 57/17) or post-IP injection of 20 mg/kg Cilobradine (n = 44/11; * p = 0.0184), and h bursting activity in VTA DA neurons during baseline conditions (0 mg/kg Cilobradine; n = 57/17) or post-IP injection of 20 mg/kg Cilobradine (n = 44/11; *** p = 0.0001). i Sample traces of baseline firing rate and firing rate following an IP injection of 1 mg/kg and 10 mg/kg MS7712. Summary and inset cumulative distribution of: j firing rate in VTA DA neurons during baseline conditions (0 mg/kg MS7712; n = 17/6) or post-IP injection of 1 mg/kg (n = 21/3) or 10 mg/kg (n = 22/3) MS7712 (H3/60 = 23.42, p < 0.0001; 10 mg/kg MS7712 vs. baseline, *** p < 0.0001), and k bursting activity in VTA DA neurons during baseline conditions (0 mg/kg MS7712; n = 17/6) or post-IP injection of 1 mg/kg (n = 21/3) or 10 mg/kg (n = 22/3) MS7712 (H3/60 = 11.38, p = 0.0034; 10 mg/kg MS7712 vs. baseline, **p = 0.0023). l Sample traces of firing rate following an IP injection of 1 and 10 mg/kg MS7710. Summary and inset cumulative distribution of m firing rate in VTA DA neurons during baseline conditions (0 mg/kg MS7710; n = 27/8) or post-IP injection of 1 mg/kg (n = 15/3) or 10 mg/kg (n = 18/3) MS7710 (H3/59 = 14.97, p = 0.0006; 1 mg/kg MS7710 vs. baseline, * p = 0.0150; 10 mg/kg MS7710 vs. baseline, *** p = 0.0007) and n bursting activity in VTA DA neurons during baseline conditions (0 mg/kg MS7710; n = 27/8) or post-IP injection of 1 mg/kg (n = 15/3) or 10 mg/kg (n = 18/3) MS7710 (H3/59 = 7.752, * p = 0.0207; 1 mg/kg MS7710 vs. baseline, * p = 0.0494; 10 mg/kg MS7710 vs. baseline, * p = 0.0364). All sample trace scale bars 0.1 mV vs. 1 s unless otherwise noted. Notation of n = ntotal cells/ntotal mice. Data are presented as median ± quartiles ± min and max, analyzed by the Mann-Whitney test for two groups or the Kruskal-Wallis test for three groups, followed by Dunn’s test for multiple comparisons. * p < 0.05, ** p < 0.01, *** p < 0.001.CC BY-NC-ND · PubMed Central
Fig. 5 Novel HCN inhibitor MS7710 reverses CSDS-induced hyperdopaminergia in female CSDS-susceptible mice. a Experimental timeline for female CSDS and in vivo electrophysiology. b SI ratios of the female CSDS mice. c Example in vivo electrophysiology traces of firing rate in VTA DA neurons in female, CSDS-susceptible mice without MS7710 (0 mg/kg, baseline) and following a 1 mg/kg IP injection of MS7710 (scale bars 0.1 mV vs. 1 s). Summary and inset cumulative distribution (dotted horizontal line represents 100%) of: d Firing rate in VTA DA neurons during baseline conditions (0 mg/kg MS7710; n = 11/3) or post-IP injection of 1 mg/kg MS7710 (n = 16/3; ** p = 0.0010), and e bursting activity in VTA DA neurons during baseline conditions (0 mg/kg MS7710; n = 11/3) or post-IP injection of 1 mg/kg MS7710 (n = 16/3; * p = 0.0246). Notation of n = ntotal cells/ntotal mice. Data are presented as median ± quartiles ± min and max, analyzed by the Mann-Whitney test for two groups. * p < 0.05, ** p < 0.01.
Fig. 5 Novel HCN inhibitor MS7710 reverses CSDS-induced hyperdopaminergia in female CSDS-susceptible mice. a Experimental timeline for female CSDS and in vivo electrophysiology. b SI ratios of the female CSDS mice. c Example in vivo electrophysiology traces of firing rate in VTA DA neurons in female, CSDS-susceptible mice without MS7710 (0 mg/kg, baseline) and following a 1 mg/kg IP injection of MS7710 (scale bars 0.1 mV vs. 1 s). Summary and inset cumulative distribution (dotted horizontal line represents 100%) of: d Firing rate in VTA DA neurons during baseline conditions (0 mg/kg MS7710; n = 11/3) or post-IP injection of 1 mg/kg MS7710 (n = 16/3; ** p = 0.0010), and e bursting activity in VTA DA neurons during baseline conditions (0 mg/kg MS7710; n = 11/3) or post-IP injection of 1 mg/kg MS7710 (n = 16/3; * p = 0.0246). Notation of n = ntotal cells/ntotal mice. Data are presented as median ± quartiles ± min and max, analyzed by the Mann-Whitney test for two groups. * p < 0.05, ** p < 0.01.CC BY-NC-ND · PubMed Central
Fig. 6 Novel HCN inhibitor MS7710 improves CSDS-induced social, reward, and cognitive deficits. a Timeline of CSDS and PRLT experimental paradigm. b Schema of SI test. c Social interaction test for male, susceptible mice before injection, and 14 days after IP injection of either saline (n = 11) or 5 mg/kg MS7710 (n = 13). 5 mg/kg MS7710 improved SI ratios (paired t-test: * p = 0.0238), and as compared to saline (Mann-Whitney test: * p = 0.831). d SI test for female, susceptible mice before injection and 14 days after IP injection of either saline (n = 10) or 5 mg/kg MS7710 (n = 9). 5 mg/kg MS7710 improved SI ratios within group (paired t-test: * p = 0.0246). e Schema of PRLT, including placement of SI tests. f PRLT correct choice in percentage during the reversal sessions post-injection for male, control (n = 18), susceptible + saline (n = 11) and susceptible + 5 mg/kg MS7710 mice (n = 13; two-way mixed effects ANOVA: effect of time: F3.336, 129.0 = 63.33, *** p < 0.0001; effect of condition: F2,39 = 4.076, * p = 0.0247; effect of time x condition: F30, 580 = 1.506, * p = 0.0425). The inset depicts the number of sessions until the criteria is reached for each condition (one way ANOVA: F2,39 = 4.539, * p = 0.02; Tukey’s test for multiple comparisons: control vs. susceptible + saline mice: * p = 0.02; susceptible + MS7710 vs. susceptible + saline mice: * p = 0.03). g PRLT correct choice in percentage during the reversal sessions post-injection for female, control (n = 6), susceptible + saline (n = 10) and susceptible + 5 mg/kg MS7710 mice (n = 9; two-way mixed effects ANOVA: effect of time: F3.539, 79.04 = 33.80, *** p < 0.0001; effect of condition: F2,23 = 3.555, * p = 0.0451; effect of time x condition: F30, 355 = 0.7913, ns p = 0.7774). The inset depicts the number of sessions until the criteria are reached for each treatment condition (one-way ANOVA: F2,22 = 4.584, * p = 0.02; Tukey’s test for multiple comparisons: control vs. susceptible + saline mice: ns p = 0.06; susceptible + MS7710 vs. susceptible + saline mice: * p = 0.04). h Pearson correlation of the SI ratio with the number of sessions to reach criteria in the PRLT following reversal for susceptible + 5 mg/kg MS7710 male mice (n = 13, r = 0.3026, p = 0.3149), and i for susceptible + 5 mg/kg MS7710 female mice (n = 9, r = -0.2230, p = 0.5642). Data are presented as mean ± SEM error bars or ribbons. * p < 0.05, ** p < 0.01, *** p < 0.001.
Fig. 6 Novel HCN inhibitor MS7710 improves CSDS-induced social, reward, and cognitive deficits. a Timeline of CSDS and PRLT experimental paradigm. b Schema of SI test. c Social interaction test for male, susceptible mice before injection, and 14 days after IP injection of either saline (n = 11) or 5 mg/kg MS7710 (n = 13). 5 mg/kg MS7710 improved SI ratios (paired t-test: * p = 0.0238), and as compared to saline (Mann-Whitney test: * p = 0.831). d SI test for female, susceptible mice before injection and 14 days after IP injection of either saline (n = 10) or 5 mg/kg MS7710 (n = 9). 5 mg/kg MS7710 improved SI ratios within group (paired t-test: * p = 0.0246). e Schema of PRLT, including placement of SI tests. f PRLT correct choice in percentage during the reversal sessions post-injection for male, control (n = 18), susceptible + saline (n = 11) and susceptible + 5 mg/kg MS7710 mice (n = 13; two-way mixed effects ANOVA: effect of time: F3.336, 129.0 = 63.33, *** p < 0.0001; effect of condition: F2,39 = 4.076, * p = 0.0247; effect of time x condition: F30, 580 = 1.506, * p = 0.0425). The inset depicts the number of sessions until the criteria is reached for each condition (one way ANOVA: F2,39 = 4.539, * p = 0.02; Tukey’s test for multiple comparisons: control vs. susceptible + saline mice: * p = 0.02; susceptible + MS7710 vs. susceptible + saline mice: * p = 0.03). g PRLT correct choice in percentage during the reversal sessions post-injection for female, control (n = 6), susceptible + saline (n = 10) and susceptible + 5 mg/kg MS7710 mice (n = 9; two-way mixed effects ANOVA: effect of time: F3.539, 79.04 = 33.80, *** p < 0.0001; effect of condition: F2,23 = 3.555, * p = 0.0451; effect of time x condition: F30, 355 = 0.7913, ns p = 0.7774). The inset depicts the number of sessions until the criteria are reached for each treatment condition (one-way ANOVA: F2,22 = 4.584, * p = 0.02; Tukey’s test for multiple comparisons: control vs. susceptible + saline mice: ns p = 0.06; susceptible + MS7710 vs. susceptible + saline mice: * p = 0.04). h Pearson correlation of the SI ratio with the number of sessions to reach criteria in the PRLT following reversal for susceptible + 5 mg/kg MS7710 male mice (n = 13, r = 0.3026, p = 0.3149), and i for susceptible + 5 mg/kg MS7710 female mice (n = 9, r = -0.2230, p = 0.5642). Data are presented as mean ± SEM error bars or ribbons. * p < 0.05, ** p < 0.01, *** p < 0.001.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 86 references

Research works printed but not linked: 2

  1. Friedrich MJ. Depression Is the leading cause of disability around the world. JAMA. 2017;317:1517.
  2. Savelieva I, Camm AJ. Novel if current inhibitor ivabradine: safety considerations. Heart Rate Slowing Curr Inhibition. 2006;43:79–96.

Cited by

See all 5

Metadata

Authors
Teichman, E. M., Hu, J., Lin, H.-Y., Fisher-Foye, R. L., Blando, A., Hu, X., Kaniskan, H. Ü., Montgomery, S. E., Cai, M., Parise, L. F., Wang, J., Russo, S. J., Han, M.-H., Jin, J., & Morel, C.
Affiliations
  • Icahn School of Medicine at Mount Sinai (US)
  • James J. Peters VA Medical Center (US)
  • Chinese Academy of Sciences (CN)
  • Tisch Cancer Institute (US)
Corresponding author
  • Han, Ming-Hu
  • Jin, Jian
  • Morel, Carole
Venue
Molecular Psychiatry
Published
2025-04-08
Volume
30
Issue
9
Pages
3937-3950
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W4409256954
Cited by
5
References
86
Citations by year
2026: 3 · 2025: 2
FWCI
2.81
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Psychiatry (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH120637, R01MH120514, F31MH131358, R01MH133299, R01MH104559, R01MH127820)
  • U.S. Department of Veterans Affairs (I01BX005722)
  • U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (1S10OD025132, 1S10OD028504)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
major depressive disorder, chronic social defeat stress, ventral tegmental area, brain penetration, social interaction deficits, cognitive inflexibility, antidepressant drug discovery, sex differences
MeSH terms
Social Defeat, Animals, Brain, Major Depressive Disorder, Disease Models, Animal, Dopamine, Male, Mice, Inbred C57BL, Phenotype, Stress, Psychological, Ventral Tegmental Area, Mice, Dopaminergic Neurons, Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design and validation of novel brain-penetrant HCN channel inhibitors to ameliorate social stress-induced susceptible phenotype. https://app.cochat.ai/papers/10.1038/s41380-025-02972-8
The paper
Teichman, E. M., Hu, J., Lin, H.-Y., Fisher-Foye, R. L., Blando, A., Hu, X., Kaniskan, H. Ü., Montgomery, S. E., Cai, M., Parise, L. F., Wang, J., Russo, S. J., Han, M.-H., Jin, J., & Morel, C. (2025). Design and validation of novel brain-penetrant HCN channel inhibitors to ameliorate social stress-induced susceptible phenotype. Molecular Psychiatry. https://doi.org/10.1038/s41380-025-02972-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.